Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma
Authors:
- Jong-Chan LeeJLJong-Chan Lee
- Kyu-Hyun PaikKPKyu-Hyun Paik
- Yoon Suk LeeYLYoon Suk Lee
- Jin-Hyeok HwangJHJin-Hyeok Hwang
- Jaihwan KimJKJaihwan Kim
Open Access
- 1 June 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 94 (25) , e1012
Abstract
Few studies have evaluated the presence of hepatic or peritoneal metastasis as a prognostic factor in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). This study aimed to elucidate the prognostic value of the initial metastatic, extrahepatic, or hepatic site in patients with metastatic PDAC. Between January 2007 and December 2013, the medical records of 343 patients with metastatic PDAC treated at Seoul National University Bundang Hospital were retrospectively reviewed. Patients were classified as having extrahepatic metastasis alone (EH), hepatic metastasis alone (LV), and both hepatic and extrahepatic metastasis (BOTH). The median age was 67 years; 207 patients were men. Patients were classified as having EH (111 patients), LV (106), and BOTH (126). Totally, 212 patients underwent chemotherapy with a FOLFIRINOX (23 patients) or gemcitabine-based regimen (189). On multivariate analysis, an ECOG score ≥2 (hazard ratio [HR]: 3.2, 95% confidence interval [CI]: 2.2–4.5), albumin < 35 g/L (HR: 1.6, 95% CI: 1.1–2.3), C-reactive protein > 10 mg/L (HR: 2.3, 95% CI: 1.6–3.2), neutrophil-lymphocyte ratio > 5 (HR: 1.4, 95% CI: 1.0–2.0), no chemotherapy (HR: 2.0, 95% CI: 1.0–4.1), and metastatic site (LV, HR: 2.1, 95% CI: 1.4–3.1; BOTH, HR: 2.2, 95% CI: 1.6–3.2) were significantly associated with shorter overall survival (OS). Considering the initial metastatic site, the median OS of patients with EH, LV, and BOTH were 7.5 (95% CI: 6.3–8.8), 4.8 (95% CI: 4.1–5.5), and 2.4 (95% CI: 1.9–2.9) months, respectively. The initial metastatic site is significantly and independently associated with OS in patients with metastatic PDAC, serving as an effective prognostic factor.Keywords
This publication has 22 references indexed in Scilit:
- Phase II study of FOLFIRINOX for chemotherapy‐naïve Japanese patients with metastatic pancreatic cancerCancer Science, 2014
- Prognostic value of systemic inflammation‐based markers in advanced pancreatic cancerInternal Medicine Journal, 2014
- A proposed model for prediction of survival based on a follow-up study in unresectable pancreatic cancerBMJ Open, 2013
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancerMedical Oncology, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic AdenocarcinomaPancreas, 2011
- The Glasgow Prognostic Score Is a Good Predictor of Treatment Outcome in Patients with Unresectable Pancreatic CancerChemotherapy, 2010
- Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.2008
- Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancerPancreatology, 2006